Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.60 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL953923 | 1.00 | GPR119 (0.60) | GPR119USP30PIK3CDALDH1A1PTPN2 | |
| SCHEMBL952021 | 1.00 | GPR119 (0.60) | GPR119USP30PIK3CDALDH1A1PTPN2 | |
| SCHEMBL951540 | 0.93 | GPR119 (0.67) | GPR119USP30ALDH1A1 | |
| SCHEMBL1769219 | 0.87 | USP30 (0.71) | GPR119USP30PIK3CD | |
| SCHEMBL5153452 | 0.87 | USP30 (0.71) | GPR119USP30PIK3CD | |
| SCHEMBL21409063 | 0.87 | USP30 (0.71) | GPR119USP30PIK3CD | |
| SCHEMBL6189661 | 0.86 | GPR119 (0.58) | GPR119USP30PIK3CDALDH1A1 | |
| SCHEMBL15376614 | 0.86 | GPR119 (0.58) | GPR119USP30PIK3CDALDH1A1 | |
| SCHEMBL699609 | 0.86 | GPR119 (0.58) | GPR119USP30PIK3CDALDH1A1 | |
| SCHEMBL20179924 | 0.86 | GPR119 (0.58) | GPR119USP30PIK3CDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399454-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-19 | — | — | US | claimed |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | claimed |
| US-8722658-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20130137674-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (US) | 2013-05-30 | — | — | US | disclosed |
| US-8399454-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | GPR119 103/4885USP30 411/4885PIK3CD 2646/4885 |
| US-20130137674-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | GPR119 103/4885USP30 411/4885PIK3CD 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.